Soluna Holdings, Inc — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Soluna Holdings, Inc filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $38.02M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $21.07M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $28.55M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $14.35M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $595.0K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $6.57M | Mar 31, 2021 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $29.72M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $38.02M | Mar 30, 2026 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2012 | Dec 31, 2012 | $5.90M | Mar 21, 2013 |
| FY2012 | Dec 31, 2011 | $10.29M | Mar 21, 2013 |
| FY2011 | Dec 31, 2010 | $8.41M | Mar 27, 2012 |
| FY2011 | Dec 31, 2009 | $8.31M | Mar 27, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.80M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($23.74M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $2.77M | Mar 31, 2025 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($53.41M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($63.33M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($29.20M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($98.72M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($5.26M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $1.95M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $323.0K | Mar 31, 2021 |
| FY2017 | Dec 31, 2017 | $582.0K | Mar 29, 2018 |
| FY2017 | Dec 31, 2016 | ($359.0K) | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | ($2.83M) | Mar 2, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($33.68M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($47.52M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($20.24M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($84.79M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($4.48M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($1.64M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $259.0K | Mar 31, 2021 |
| FY2017 | Dec 31, 2017 | $588.0K | Mar 29, 2018 |
| FY2017 | Dec 31, 2016 | ($361.0K) | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | ($1.47M) | Mar 2, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $1.49M | Mar 31, 2021 |
| FY2020 | Dec 31, 2019 | $1.38M | Mar 31, 2021 |
| FY2017 | Dec 31, 2017 | $1.15M | Mar 29, 2018 |
| FY2017 | Dec 31, 2016 | $1.24M | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | $1.55M | Mar 2, 2017 |
| FY2015 | Dec 31, 2014 | $1.35M | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | $1.32M | Mar 5, 2015 |
| FY2012 | Dec 31, 2012 | $1.36M | Mar 21, 2013 |
| FY2012 | Dec 31, 2011 | $1.47M | Mar 21, 2013 |
| FY2011 | Dec 31, 2010 | $3.86M | Mar 27, 2012 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $40.13M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $28.19M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $24.90M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $28.71M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $10.75M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $1.83M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $2.73M | Mar 31, 2021 |
| FY2017 | Dec 31, 2017 | $3.09M | Mar 29, 2018 |
| FY2017 | Dec 31, 2016 | $3.45M | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | $3.78M | Mar 2, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($9.15M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($5.07M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($2.99M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($6.12M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $4.64M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($1.21M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $289.0K | Mar 31, 2021 |
| FY2017 | Dec 31, 2017 | $363.0K | Mar 29, 2018 |
| FY2017 | Dec 31, 2016 | $522.0K | Mar 29, 2018 |
| FY2013 | Dec 31, 2013 | $1.0K | Mar 6, 2014 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $28.07M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $8.85M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $12.71M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $63.68M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $45.79M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $805.0K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $83.0K | Mar 31, 2021 |
| FY2017 | Dec 31, 2017 | $107.0K | Mar 29, 2018 |
| FY2017 | Dec 31, 2016 | $136.0K | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | $55.0K | Mar 2, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $187.94M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $88.04M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $91.28M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $84.96M | Apr 1, 2024 |
| FY2022 | Apr 11, 2022 | $2.88M | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | $117.69M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $8.65M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $5.75M | Mar 31, 2021 |
| FY2017 | Dec 31, 2017 | $6.20M | Mar 29, 2018 |
| FY2017 | Dec 31, 2016 | $5.18M | Mar 29, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $75.70M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $60.68M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $37.92M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $38.69M | Apr 1, 2024 |
| FY2022 | Apr 11, 2022 | $1.25M | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | $26.71M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $2.73M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $1.92M | Mar 31, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $53.55M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($12.48M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $26.51M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $41.87M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $90.99M | Mar 31, 2023 |
| FY2022 | Sep 30, 2021 | $38.73M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $5.92M | Mar 31, 2022 |
| FY2021 | Dec 31, 2019 | $3.83M | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | $6.95M | Mar 31, 2021 |
| FY2017 | Dec 31, 2017 | $4.96M | Mar 29, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($367.72M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($314.30M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($250.97M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($221.77M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($123.05M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($117.79M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($119.74M) | Mar 31, 2021 |
| FY2017 | Dec 31, 2017 | ($120.40M) | Mar 29, 2018 |
| FY2017 | Dec 31, 2016 | ($120.98M) | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | ($120.62M) | Mar 2, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2015 | $462.0K | Mar 30, 2016 |
| FY2015 | Dec 31, 2014 | $1.92M | Mar 30, 2016 |
| FY2015 | Dec 31, 2013 | $1.21M | Mar 30, 2016 |
| FY2014 | Dec 31, 2012 | $289.0K | Mar 5, 2015 |
| FY2013 | Dec 31, 2011 | $1.7K | Mar 6, 2014 |
| FY2012 | Dec 31, 2010 | $1.12M | Mar 21, 2013 |
| FY2011 | Dec 31, 2009 | $785.0K | Mar 27, 2012 |
| FY2011 | Dec 31, 2008 | $1.66M | Mar 27, 2012 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.90M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $7.06M | Mar 30, 2026 |
| FY2025 | Jul 22, 2024 | $2.16M | Mar 30, 2026 |
| FY2022 | Dec 31, 2022 | $13.00M | Mar 31, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 30, 2026 |
| FY2025 | Jun 30, 2025 | 0 | Mar 30, 2026 |
| FY2025 | Mar 31, 2025 | (1) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | (14) | Mar 30, 2026 |
| FY2025 | Sep 30, 2024 | (1) | Mar 30, 2026 |
| FY2025 | Jun 30, 2024 | (3) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | (27) | Mar 31, 2025 |
| FY2023 | Sep 30, 2023 | (5) | Apr 1, 2024 |
| FY2023 | Jun 30, 2023 | (9) | Apr 1, 2024 |
| FY2023 | Mar 31, 2023 | (10) | Apr 1, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 30, 2026 |
| FY2025 | Jun 30, 2025 | 0 | Mar 30, 2026 |
| FY2025 | Mar 31, 2025 | (1) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | (14) | Mar 30, 2026 |
| FY2025 | Sep 30, 2024 | (1) | Mar 30, 2026 |
| FY2025 | Jun 30, 2024 | (3) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | (27) | Mar 31, 2025 |
| FY2023 | Sep 30, 2023 | (5) | Apr 1, 2024 |
| FY2023 | Jun 30, 2023 | (9) | Apr 1, 2024 |
| FY2023 | Mar 31, 2023 | (10) | Apr 1, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 102.53M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 10.61M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 2.51M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 747,837 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 13.75M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 10.75M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 9.57M | Mar 31, 2021 |
| FY2020 | Dec 31, 2018 | 9.44M | Mar 31, 2021 |
| FY2017 | Dec 31, 2017 | 9.36M | Mar 29, 2018 |
| FY2017 | Dec 31, 2016 | 9.01M | Mar 29, 2018 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $0 | Mar 31, 2021 |
| FY2020 | Dec 31, 2019 | $3.54M | Mar 31, 2021 |